Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 672-677

  Schuster, Jean Pierre ^a,b   Raucher Chéné, Delphine ^c   Lemogne, Cédric ^b,d,e   Rouillon, Frédéric ^b,e,f   Gasquet, Isabelle ^g,h   Leguay, Denis ⁱ   Gierski, Fabien ^c   Azorin, Jean Michel ^j   Limosin, Frédéric ^a,b,e  

^a Paris Descartes University   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f Sainte Anne Hospital   (France)

^g Universite Paris Sud   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ Department of Psychiatry   (France)

^j HÔPITAL SAINTE MARGUERITE   (France)

more..

Author keywords

adverse effects; antipsychotics; body mass index; schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; CLOZAPINE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; WEIGHT LOSS;

EID: 84865860466     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31826866db     Document Type: Article

References (22)

1. Limosin F, Gasquet I, Leguay D, et al. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand. 2008;118(1):19-25.
2. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001;46(6):549-555.
3. Citrome L. Balancing efficacy against the risk of weight gain. J Clin Psychiatry. 2007;68(suppl 12):12-17.
4. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
5. Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second generation antipsychotics on body weight and metabolismVrisk assessment and results from a prospective study. Pharmacopsychiatry. 2009;42(1):29-34.
6. Clark SL, Adkins DE, van den Oord EJ. Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res. 2011;132:114-120.
7. Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116(5):317-333.
8. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131.
9. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66(1):51-57.
10. American Diabetes Association; American Psychiatric Association, American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
11. Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010; 8(12):CD006629.
12. McElroy SL. Obesity in patients with severe mental illness: overviewand management. J Clin Psychiatry. 2009;70(suppl 3):12-21.
13. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121e8.
14. World Health Organization. Physical Status: The Use and Interpretation of Anthropometry. Report of a World Health Organization Expert Committee. WHO Technical Report Series 854. Geneva, Switzerland: WHO; 1995.
15. Allison DB, Newcomer JW, Dunn AL, et al. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med. 2009;36(4):341-350.
16. Tarricone I, Ferrari Gozzi B, Serretti A, et al. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40(2):187-200.
17. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009;43(6):620-626.
18. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;7:4.
19. Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. J Obes. 2011; 898013.
20. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041-1050.
21. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68(suppl 4):34-39.
22. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;699(suppl 1):4-17.